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ABSTRACT Small-molecule target identiﬁcation is a vital and daunting task for
the chemical biology community as well as for researchers interested in applying
the power of chemical genetics to impact biology and medicine. To overcome this
“target ID” bottleneck, new technologies are being developed that analyze
protein–drug interactions, such as drug afﬁnity responsive target stability
(DARTS), which aims to discover the direct binding targets (and off targets) of
small molecules on a proteome scale without requiring chemical modiﬁcation of
the compound. Here, we review the DARTS method, discuss why it works, and pro-
vide new perspectives for future development in this area.
H
umans have been using small molecule drugs
for their medicinal, hallucinogenic, and toxic
properties for at least thousands of years; the
oldest materia medica might be traced back to the leg-
endary Shen Nong (the Divine Farmer) of 2737 B.C. Un-
til very recently, Nature was the exclusive source of all
such drugs. There are literally millions of species of
plants, fungi, bacteria, and animals on Earth that pro-
duce a plethora of compounds with equally diverse
chemical structures and pharmacological properties,
many of which are still unknown to man. Only in the last
one and a half centuries, and mainly during the past
fewdecades,havewebeguntoacquiretheabilitytocre-
ate ourselves compounds with desired properties, such
as binding to and modulating the activity (or expres-
sion) of speciﬁc proteins (1–15). That being said, even
whennotusingnatureasthedirectsourceofnewdrugs,
we still often rely on inspiration from natural product
compounds in our search for new medicines (16–18).
Studies on the molecular mechanism of action of natu-
ral small molecules has also long been a goldmine for
identifying the function and importance of proteins from
many classes, including membrane and intracellular re-
ceptors, signaling proteins, and proteins involved in
regulatingandcarryingoutthecellcycle,cellgrowth,mi-
tosis, DNA replication and repair, transcription, and
translation (reviewed in refs 19–21).
A large percentage of compounds of current interest
were derived from screens using cell culture or whole or-
ganisms and phenotypic or molecular readouts (22–
30). While the opportunity for ﬁnding novel drugs or
drug uses from such assays is high, their primary limita-
tion is that they typically give no indication of the poten-
tial drug targets, and ﬁnding the direct targets is often
the most challenging and time-consuming step of the
project. Moreover, drugs screened for or designed to
speciﬁcally modulate activity of a given protein of inter-
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of which may not be predicted simply by sequence or
structural homology.
Although mechanistic studies of drug action has a
long history, identiﬁcation of the direct targets of drugs
has its roots in the pioneering work on afﬁnity chroma-
tography, biochemical fractionation, and radioactive li-
gand binding assays. Afﬁnity puriﬁcation of enzymes
withsmallmoleculeinhibitorswasﬁrstdevelopedinthe
early 1950s by Leonard Lerman (31) and subsequently
used for novel identiﬁcations by the McCormick and An-
ﬁnson laboratories during the 1960s (32, 33). Around
the same time others had begun to use radioisotope-
labeled compounds and biochemical fractionation to
enrich drug-binding proteins from crude tissue extracts
and cell lysates (34–38). Starting with the proof of exist-
ence by puriﬁcation of the lac repressor protein by Wally
Gilbert, using radioligand binding measured by equilib-
rium dialysis as an assay (39), radioligand binding
quickly became a successful method to identify recep-
tors for hormones and neurotransmitters. Cuatrecasas
isolated the insulin receptor, a very low abundance
protein, using radioactive insulin binding and insulin co-
valently linked to agarose beads for afﬁnity chromatog-
raphy (reviewed in ref 40). Sol Snyder and colleagues
discovered the opiate receptors in brain using a radio-
ligand binding assay (41), assisting the demonstration
and identiﬁcation of endogenous opioid peptides and
their myriad biological functions. He followed this with
rapididentiﬁcationofthe10mostimportantneurotrans-
mitter receptors, which hundreds of other workers had
been attempting unsuccessfully for years. His success
came from identiﬁcation of suitable high afﬁnity and
high speciﬁcity ligands and the know-how to employ
them properly. The ﬁrst neurotransmitter receptor to be
puriﬁed was the nicotinic acetylcholine receptor, using
radioactive snake toxin as a binding assay and small
molecule afﬁnity chromatography (as well as a tissue
source with high expression, electric rays and eels) (42).
The ﬁrst direct identiﬁcation of amino acids involved in
general anesthetic binding (etomidate) in its biotarget,
GABA-A receptors in brain, has used photoafﬁnity label-
ing with a photoincorporatable radiolabeled aziridine
analogue of etomidate that retained anesthetic activity
and microsequencing (43). Many prominent natural
product target identiﬁcations have made use of one of
these two techniques (44–52). Today, afﬁnity chroma-
tography, also known as afﬁnity puriﬁcation, has be-
come the most-used method (53), but radioafﬁnity and
photoafﬁnity approaches occasionally ﬁnd use (54).
Afﬁnity Chromatography as a Classical Method for
Target ID. Despite the large number of target identiﬁca-
tion techniques described to date, afﬁnity chromatogra-
phy remains the most widely used method (55, 56).
The typical project begins with structure–activity rela-
tionship (SAR) studies in which various functional
groups of the small molecule of interest are modiﬁed
or removed to determine which one(s) are dispensable
for drug activity. These nonessential site(s) are then
used as points of attachment to an afﬁnity tag (e.g., bio-
tin) or solid matrix (e.g., Afﬁ-Gel agarose beads). Then,
much like is performed during immunoprecipitation of
speciﬁc proteins using an antibody and Protein A/G-
conjugated beads, the drug-linked beads are incubated
with protein extracts, followed by extensive washing to
remove nonspeciﬁcally bound proteins. Finally the
tightly binding proteins are eluted with excess free drug
or under highly denaturing conditions. Most often the
eluted proteins are subsequently analyzed by SDS–
PAGE and protein bands are identiﬁed by mass spec-
trometry. Given that there are typically many more non-
speciﬁc binders than actual drug targets, negative
control experiments using similarly tagged inactive ana-
logues of the parental compound are performed simul-
taneously when possible. Once potential targets are
identiﬁed,subsequentstudiesmustconﬁrmdirectbind-
ing as well as its biological importance.
The primary limitation of afﬁnity chromatography is
the need to derivatize the small molecules of interest.
SAR studies are time-consuming and require extensive
medicinal chemistry expertise that is often lacking in the
academic laboratories performing forward chemical
genetics and phenotypic small molecule screens. Even
when available, many small molecules cannot be modi-
ﬁed without affecting bioactivity, and presumably bind-
ing,orcannotbeeasilyobtainedorsynthesizedinquan-
tities large enough to permit SAR and subsequent
studies. However, in comparison to other newly devel-
oped target identiﬁcation methods that rely on various
phenotypic or molecular signatures to narrow down po-
tential targets, the advantage of afﬁnity-based methods
is that they rely solely on binding of the drug to its tar-
get protein, rather than speciﬁc cellular or biochemical
readouts that are only useful for a fraction of com-
pounds (reviewed in refs 57–62).
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phy approach for target identiﬁcation takes advantage
of the quantitative capability of SILAC to drastically in-
crease the sensitivity of this approach for target identiﬁ-
cation (63). This quantitative proteomic approach elimi-
nates the need to visualize the target protein by gel
staining, instead relying upon identiﬁcation of the tar-
get by tandem mass spectrometry, which also allows
the identiﬁcation of multiple targets (polypharmacol-
ogy). Furthermore, by comparison of the target pull-
down with a well-designed control pull-down, true tar-
get proteins can be more easily distinguished from the
many nonspeciﬁc binders due to their unique enrich-
mentinthetargetpull-downsample.Whilethisdevelop-
ment is likely to enhance many target identiﬁcation
projects, it is still reliant upon SAR studies and limited
to small molecules with derivatizable moieties. It is also
contingent on the availability of a suitable inactive small
molecule that can serve as the negative control, which
is often not possible to obtain.
In summary, afﬁnity chromatography of small mol-
eculesisseverelylimitedduetothevaststructuraldiver-
sity and complexity of biologically active small mol-
ecules. Unlike afﬁnity fusion (e.g., to glutathione
S-transferase, or GST) and iodination of peptides, which
are carried out routinely by the standard molecular bio-
logical (64, 65) and chloramine-T (66, 67) methods, re-
spectively, no universal or simple solution has been ob-
tained to immobilize or label organic compounds.
Drug Afﬁnity Responsive Target Stability (DARTS).
Given the shortcomings of current target identiﬁcation
methodologies, a breakthrough will likely require think-
ing outside the “chemically modifying the small mol-
ecule” box. We imagined that a target identiﬁcation
strategy that only relied on drug–protein binding yet
did not require modiﬁcation of the small molecule
would be ideal. Such an approach could potentially
identify any protein targets of small molecules with no
limitations posed by chemistry or mechanism of action.
The idea that a small molecule drug would stabilize its
target protein’s structure and result in protease resis-
tance offered a possible solution to the problem of tar-
get identiﬁcation, so long as the decreased proteolysis
couldbereadilydetectedincomplexsamples.Stabiliza-
tion of lysozyme structure upon substrate binding is a
well-known phenomenon that has been demonstrated
by increased resistance to denaturation by heat and
chaotropic agents (68). This enhanced stability is postu-
lated to result from a shift in the thermodynamic land-
scape of the protein to favor the ligand-bound state,
which prevents much of the protein’s innate ﬂexibility
and movement (or protein “breathing”) (69–71) from
being realized (Figure 1). One recent example that lends
support for this model comes from the ﬁnding that
FK506, which protects FKBP12 in DARTS (62), leads to
stabilization of a high-energy backbone conformation
that is otherwise minorly populated in the native confor-
mational ensemble of free FKBP12 (72). Ligand-induced
stabilization has been exploited by numerous tech-
niques to detect and analyze speciﬁc protein–ligand in-
teractions (73–77). It has also been instrumental for
puriﬁcation of natively folded recombinant proteins and
subsequent structural determination by protein crystalli-
zation (78, 79). Even ligand-induced resistance to pro-
teolysis turns out to not be a completely new idea, as it
was amply demonstrated for serum albumin (80, 81),
Staphylococcal nuclease and nuclease-T (82), ﬁreﬂy lu-
ciferase (83), etc. However, very few prior reports de-
tailed small molecule-induced protease resistance, and
there certainly had been no realization that it may be
general enough to be used as a discovery approach for
identifying unknown targets. Our work has shown just
Figure 1. Theoretical model for why DARTS works. Under
physiological conditions a protein is in dynamic equilib-
rium with multiple alternative conformations and may also
exhibit some level of local, reversible unfolding (69, 71,
126, 127). Upon saturation with a speciﬁc ligand, the equi-
librium will shift to highly favor the conformation bound
by the ligand as a result of the negative free energy
change due to hydrophobic, hydrogen bonding, and/or
electrostatic interactions that are formed between the
protein and the drug ligand. This leads to a thermodynami-
cally more stable state in which the target protein’s con-
formational ﬂuctuations (“breathing”) and unfolding are
dramatically decreased and resistance to denaturation and
DARTS proteolysis is markedly increased. (The fate of the
target protein in vivo, on the other hand, cannot be pre-
dicted; ligand binding can cause either increase, decrease,
or no change in the stability and/or expression of its tar-
get depending on the biology (62). )
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the potential of utilizing it for target identiﬁcation (62)
(Table 1).
DARTS offers an unprecedented ability to identify
new proteins targeted by small molecules. It is similar
to afﬁnity chromatography in that both are afﬁnity-
based methods that start with complex protein samples
and selectively enrich the target protein(s) while deplet-
ing all nontarget proteins. However, whereas afﬁnity
chromatography utilizes positive enrichment by selec-
TABLE 1. Small molecule–protein interactions conﬁrmed or identiﬁed by DARTS
a
aN/D: direct binding not determined. IVT: in vitro translated. DSF: differential scanning ﬂuorimetry.
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nontargets, DARTS uses negative enrichment by digest-
ing away nontarget proteins while leaving behind the
target proteins that are rendered protease-resistant
(Figure 2). With several decades of afﬁnity chromatogra-
phy usage, its strengths and limitations have been well
characterized. For example, a primary weakness is the
often-high level of nonspeciﬁc binding of nontarget
proteins to the matrix, which confounds isolation of the
true targets. Although extensive washing of the matrix
can help reduce the number of nonspeciﬁc binders,
weaker true interactors will often be lost during the pro-
cess. In contrast, DARTS does not require washing and
can be used to analyze lower afﬁnity interactions.
DARTS is also unique in that native small molecules
are used without the need for chemical derivatization
or even knowing the chemical identity or purity of the
compound. As such, DARTS allows bioactive natural
product extracts to be used for target ID prior to fraction-
ation,thusenablingresearchofnotonlypolypharmacol-
ogy (95) but also polypharmacy (e.g., Chinese herbal
medicine). This is a tremendous advantage over afﬁnity
chromatography and other prior methods.
Additional Protein-Based Target ID Platforms.
Proteome Chips. The advent of proteome microarrays
has revolutionized the global analysis of the biochemi-
cal activities of proteins, including the study of protein–
small molecule interactions
(96). In this method, small
molecules are ﬁrst labeled
such that their physical pres-
ence and location can be fol-
lowed upon binding to the
proteome chip (24). Com-
mon labels used for afﬁnity
chromatography can also be
used to probe proteome
chips, including afﬁnity tags
(e.g., biotin), ﬂuorescence
tags, photochemical tags,
and radioisotopes (97, 98).
A key advantage is the abil-
ity to analyze drug binding
on a whole-proteome scale
in a microarray format, re-
vealing all binding targets,
including “off-targets”. How-
ever, a current disadvantage
shared with afﬁnity chromatography is the need for
small-molecule labeling and the requirement that the la-
beling moiety can be incorporated without abolishing
the compound’s bioactivity. The power of this approach
will be greatly enhanced by the development of label-
free binding detection compatible with the proteome ar-
ray format (99).
ABPP. A chemical proteomic approach that accesses
protein targets via the use of reactive small molecule
probes also constitutes a powerful means for identify-
ing unknown targets. For example, activity-based
protein proﬁling (ABPP) relies on small molecules con-
taining reactive functional groups (mainly electrophiles)
that can covalently attach to catalytic residues in an en-
zyme active site (100–103) (reviewed in ref 104). Such
activity-based probes allow the targeted enzymes to be
labeled for puriﬁcation and analysis. Many ﬂavors of
ABPs have been created, including photoactivatable,
radioactive, and biotinylated (105, 106), which greatly
facilitates both discovering novel enzymes and inhibi-
tor screening (reviewed in refs 54 and 107). Covalent
linkage between a reactive probe and its target can thus
serve the purpose for target identiﬁcation (52, 108), al-
though the requirement for derivatization of each small
molecule still exists.
SPROX. In the realm of using label-free small mol-
ecules for binding target identiﬁcation, another afﬁnity-
based label-free methodology was introduced in 2010
(109). Stability of proteins from rates of oxidation
(SPROX) is similar to DARTS in that it detects small
molecule-induced changes in the folding and thermody-
namic stability of target proteins in complex samples
(109). Instead of using differential proteolysis as a read-
out, SPROX measures ligand-induced changes in the
rate of methionine oxidation for target proteins. This ap-
proach is similar in essence to hydrogen–deuterium ex-
change, which has been used extensively to analyze
protein–ligand interactions and determine ligand bind-
ing domains within individual proteins, except that me-
thionine oxidation levels are more readily measurable in
complex protein mixtures (110, 111). Although SPROX
clearly has many of the same advantages as DARTS, it
has many additional limitations. The major limiting fac-
tor of SPROX is that only the most abundant proteins in
each sample can be identiﬁed and accurately quanti-
ﬁed. Unlike afﬁnity chromatography and DARTS, SPROX
has no mechanism to enrich the target proteins from
nontarget proteins. Therefore, obtaining proteome-wide
KEYWORDS
2D-PAGE: A two-dimensional gel-based method
that combines isoelectric focusing and SDS–
PAGE to separate proteins by charge and
molecular weight.
Afﬁnity chromatography: Traditional method of
target identiﬁcation that uses immobilized
small molecules to pull down binding
proteins from a complex protein mixture.
Degradomics: The subﬁeld of proteomics
devoted to the study of proteases and their
biological substrates.
Drug afﬁnity responsive target stability (DARTS):
A method for target identiﬁcation that relies
on drug-induced protease resistance.
MudPIT: A gel-free proteomics technique that
uses online separation of tryptic peptides by
strong cation exchange and reversed-phase
HPLC to analyze very complex protein
mixtures by mass spectrometry.
SILAC: Stable isotope labeling of amino acids in
cell culture.
Target identiﬁcation: Determination of which
proteins a particular small molecule binds in
the cell.
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require extensive up-front frac-
tionation of the sample. Addi-
tionally, only methionine-
containing peptides are useful
with SPROX analysis, and not
all methionine residues exhibit
differential oxidation rates in-
formative for determining ther-
modynamic changes. This is in
contrast to the DARTS and af-
ﬁnity chromatography which
can utilize information from
any identiﬁable peptides.
Methodology and Practice
of DARTS. The simplest proce-
dure for DARTS simply involves
separation of compound-
treated and control protein
samples digested with varying
amounts of protease by 1D
SDS–PAGE, staining the gel
with Coomassie Blue, Sypro
Ruby, or silver stain, and ana-
lyzing the respective lanes of
the gel for bands that are more
intense in one sample over
the other. Upon ﬁnding a band
whose abundance differs be-
tween the compound-treated
and control samples, each
band can be cut out, digested
with trypsin, and analyzed by
liquid chromatography
coupled to tandem mass spec-
trometry (LCMS/MS). After
annotating the peptides and
proteins identiﬁed in each gel
band, label-free quantitative
analysis using spectral count-
ing, LC/MS extracted ion currents (XIC), or MS/MS total
ion current (TIC) can determine which identiﬁed protein
has been enriched in your DARTS experiment (112–
114). Despite its simplicity, we have shown the utility
of the 1D gel approach for identifying previously known
and novel drug targets with DARTS (62).
The initial success of DARTS with 1D gels is likely
due to two factors: the targets of the chosen small mol-
ecules are both high abundance proteins, and neither
protein is extremely sensitive or resistant to the pro-
teases used (62). Given the need not only to visualize
the target protein on the gel but also to determine that
it is more abundant in one lane versus another, it is not
hard to imagine that many potential drug targets would
be missed by this nonsensitive analytical approach. The
target protein could either not be sufﬁciently abundant
Figure 2. Comparison of afﬁnity chromatography and DARTS. (A) Using small mol-
ecule afﬁnity chromatography, protein lysates are incubated with the immobilized
small molecule to positively enrich target proteins. Unbound proteins are washed
away, followed by elution of the target proteins with excess free drug. (B) With
DARTS, protein lysates are incubated with native drug and then treated with pro-
teases. The target proteins are negatively enriched due to their drug-induced pro-
tease resistance while nontarget proteins are digested away.
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enough to see, its enrichment in one sample over an-
other could be masked because the protein comigrates
with many other proteins of the same molecular weight
on the gel. If just one of these comigrating proteins is
much more abundant than your target protein, the fact
that it is present at the same amount in both samples
will hide the fact that the target protein is highly en-
riched in one sample. Moreover, the presence of sev-
eral low or moderately abundant proteins could just as
easily mask the differential abundance of the comigrat-
ing target protein. Given the limitations of this approach
to DARTS, our lab and others are currently pursuing sev-
eral different proteomics (mainly mass spectrometry)
and nonproteomics (mainly cDNA based) platforms that
offer vastly increased sensitivity and throughput; only
the proteomics approaches will be discussed herein.
Perspective for Future Advances in DARTS.
Proteomics. Perhaps the easiest way to more readily
detect changes in protein levels between samples is to
perform two-dimensional gel electrophoresis, also
known as 2D-PAGE, in which proteins are ﬁrst sepa-
rated by charge in the ﬁrst dimension, followed by SDS–
PAGE in the second dimension (115). The two orthogo-
nalseparationtechniquesutilizedby2D-PAGEallowsfor
more sensitive visualization of changes in protein abun-
dance between samples because only proteins with
the same isoelectric point and molecular weight will be
present in the exact same spot on the gel. Whereas with
1D SDS–PAGE a single band on the gel will likely con-
tain many, potentially dozens of different proteins, most
spots on a 2D gel will consist of a single or very small
number of proteins. Therefore, abundance differences
in single proteins between two samples are much less
likely to be masked by other comigrating proteins in 2D-
PAGE. Additionally, the development of difference gel
electrophoresis (DIGE) allows for even more sensitive
analysis of protein abundance differences. With DIGE,
two or three samples are analyzed simultaneously by la-
beling proteins in each sample with differently colored
ﬂuorescent tags, which are then combined and sepa-
rated on a single 2D gel (116). Through automated
quantitative analysis of ﬂuorescent signals at each gel
spot, similar to a microarray for gene expression analy-
sis, this method eliminates the challenge of comparing
all the spots between two or more separate gels, as well
as any worries about reproducibility of protein migra-
tionpatternsbetweenmultiplegels.Anyspotthatexhib-
its differential abundance can then be identiﬁed by
MALDI–MS or LC–MS to identify the putative target
protein.
An alternative proteomics approach that can poten-
tially be paired with DARTS is multidimensional protein
identiﬁcation technology (MudPIT) (117). MudPIT is
analogous to 2D-PAGE in the idea that two orthogonal
separation techniques are used to provide enhanced
coverage of proteins, yet it provides several fold higher
sensitivity over 2D-PAGE. Rather than separate intact
proteins, however, MudPIT is performed on the tryptic
peptides derived from complex protein samples. The
peptides are ﬁrst separated by charge using strong cat-
ion exchange (SCX). As the peptides are eluted from the
SCX phase, they directly enter the second separation
phase consisting of C18 reversed-phase matrix, which
then fractionates the peptides based on hydrophobic-
ity just as in traditional LC–MS analysis. After elution
from the reversed-phase matrix the peptides are directly
sprayed into the mass spectrometer for analysis. This
method eliminates the use of gels, as well as the need
to visually analyze your samples to ﬁnd differentially
abundant proteins. Two or more samples can be ana-
lyzed by MudPIT separately using spectral counting or
other label-free methods for quantitative analysis. Alter-
natively, multiple samples can be labeled using SILAC,
ICAT, or iTRAQ and analyzed together in a single MudPIT
run for even more sensitive quantitative comparison
(118–120).
We have devised a strategy in which the protein
samples after DARTS protease treatment are dialyzed
to remove all the small peptides and amino acids result-
ing from digestion, enriching the samples with intact
proteins or protein fragments above a given molecular
weight (e.g., 10 kDa). After dialysis, the samples are
trypsin digested in solution and subjected to MudPIT
analysis (Figure 3). The dialysis step is necessary be-
cause the large number of small, nontryptic peptides
generated during the DARTS protease treatment would
compete with tryptic peptides during the MudPIT analy-
sis both for binding to the SCX and reversed-phase ma-
tricesaswellasforMS/MSanalysisbytheiontrapmass
spectrometer. Their elimination from the sample greatly
reduces the sample complexity and increases the likeli-
hood of identifying target proteins of the small mol-
ecules under study. This approach is potentially much
more sensitive than a gel-based approach and is com-
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titative methods.
Degradomics. In addition to the arsenal of proteom-
ics tools already described, new developments in a sub-
ﬁeld of proteomics called degradomics may also be ap-
plicable in DARTS. The degradomics ﬁeld is devoted to
the study of proteases and the identiﬁcation of all their
biological substrates, aka degradomes, and many inge-
nious techniques have been developed and used to
successfully identify hundreds of previously unknown
protease substrates (reviewed in refs 121–123).
Whereas degradomics aims to identify those few
proteins that are proteolyzed against a larger back-
ground of undigested proteins, DARTS seeks to ﬁnd
those few proteins that are either not digested or are di-
gested to a lesser extent in one sample versus another,
against a larger background of proteins that are equally
digested in both samples. Despite these differences, we
anticipate that current and future developments in de-
gradomicscouldhaveanenormousimpactonDARTSby
facilitating identiﬁcation of proteins that are differen-
tially proteolyzed in the presence of small molecule
drugs and ligands.
Experimental Conditions. In addition to using more
sensitive proteomics techniques, the choice of pro-
tease, lysis buffer, and detergents may also inﬂuence
the likelihood of successfully identifying drug targets
with DARTS. The goal of current methods development
is to maximize digestion of all nontarget background
proteins without compromising the protection of the tar-
get protein, as well as to minimize the number of condi-
tions that must be tried for each drug. An ideal DARTS
condition would be one in which all proteins are di-
gested at the same rate and extent so that the only in-
tact proteins remaining after proteolysis would be drug
targets. However, given the huge diversity of protein se-
quences, structures, conformational dynamics, com-
plexes and interactions, it is no surprise that proteins
vary dramatically in their sensitivity to proteolysis. Fur-
thermore, given that different proteases target speciﬁc
residues or short motifs for degradation sites as well as
haveavarietyofpreferencesforfoldingorlocationofthe
recognition site within a polypeptide, proteome-wide
susceptibility to proteolysis also varies depending on
the protease used.
The initial use of thermolysin and a gentle, nondena-
turing lysis buffer meant that only proteins that sponta-
neously unfold or have native unstructured regions
could be digested, despite it being rather nonspeciﬁc
with regards to substrate sequence. While the protec-
tion from thermolysin proteolysis in DARTS experiments
was exceptionally robust, presumably because binding
ofthedrugspreventedunfoldingofthetargetproteins,a
large fraction of background proteins always remained
that were refractory to thermolysin digestion. This com-
plicated proteomic analysis because the remaining
samples were very complex, biasing all identiﬁcations
toward high abundance proteins. Furthermore, if the
drug target had been among those proteins not digest-
ible by thermolysin, it would never be identiﬁed by
DARTS. To overcome this, we ﬁrst tried another single
protease that can digest natively folded and denatured
proteins. Using subtilisin we were able to protect target
proteins, albeit to a lesser extent, under conditions in
which almost all proteins were at least partially di-
gested. Subsequently we reasoned that a mixture of
many different proteases with various substrate speci-
ﬁcities might work even better than any single protease.
This seems to be generally true, as the commercially
Figure 3. Combined DARTS-MudPIT approach. Protein ly-
sates are split into two and incubated with the small mol-
ecule or solvent as a control. After proteolysis, each
sample is dialyzed to remove digested peptides, followed
by MudPIT analysis to look for enriched proteins in the
drug-containing sample. Quantitation can be performed
with any isotopic-labeling strategy or using label-free ap-
proaches (see text).
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that digest native and unfolded proteins, can digest all
proteins to a similar extent as subtilisin while allowing
for a high level of protection similar to that seen with
thermolysin. It is conceivable that other homemade pro-
tease mixtures could be optimized for DARTS that would
not suffer from lot-to-lot variability as does a crude ex-
tract like Pronase (which, nevertheless, can be “cali-
brated” using homemade protein or lysate standards).
Another rather simple approach to maximize sensitiv-
ity is to perform subcellular fractionation prior to DARTS
analysis. This could particularly be useful when the tar-
get of a given drug is believed or known to reside in a
speciﬁc cellular compartment, such as the nucleus, mi-
tochondria, ER, Golgi, or plasma membrane. Simple and
robust methods already exist to purify each of these
subcellular structures to near homogeneity from a vari-
ety of cell and tissue types. The proteins isolated by
most subcellular fractionation techniques are natively
folded and fully compatible with DARTS analysis. In-
deed, such an approach to improve sensitivity of target
identiﬁcation has been used with other afﬁnity-based
approaches (124).
DrugScreeningwithDARTS.Inadditiontotargetiden-
tiﬁcation, protease resistance in DARTS can also poten-
tially be used as a screening readout. Although protein
stability measurements made by differential scanning
ﬂuorimetry (DSF), differential static light scattering
(DSLS), and isothermal denaturation (ITD) are readily
performed in microscale and can be rapidly adapted to
high-throughput screening of nearly any protein regard-
less of whether function has been demonstrated, these
methods all require relatively large amounts of pure
protein in order to screen large compound libraries
(125). On the other hand, DARTS is unique in that it
does not require using pure proteins. While DARTS can
be performed with pure protein as well, its main advan-
tage is that the level of protein purity is not a concern.
Moreover, by using miniaturization techniques, high-
throughput small-molecule DARTS screening could be
performed against any protein in a complex protein mix-
ture. Screening with DARTS, like DSF, DSLS, and ITD,
has the potential of identifying compounds that bind to
a large number of sites on the target protein. Such mol-
ecules may be activators or inhibitors of the protein that
can individually or in combination serve as leads for
speciﬁc probes useful for dissecting its molecular func-
tions across cell types and species.
Conclusions. Drug target identiﬁcation has been a
decades-long quest that until recently was largely domi-
nated by a single technique, afﬁnity chromatography,
with minimal improvements. However, with the intro-
duction of many newer afﬁnity-based and afﬁnity-free
approaches with diverse chemical and biological mech-
anisms for identifying drug targets, it may be difﬁcult to
choose which methods to use for a particular project.
Methods that require extensive research resources or
technical expertise have a high “activation barrier”,
which often precludes them from being used regard-
less of their likelihood of success. Furthermore, a priori
prediction of the methods most likely to work for a given
drug is usually not possible.
Although in its infancy, DARTS has the potential to
be a major player in drug target identiﬁcation. The
DARTS phenomenon holds over such a wide range of
molecules(evenforhigh-micromolarligands)andcondi-
tions (buffers, detergents, proteases, etc.) that essen-
tially no (or little) experimental optimization is required.
Getting started with DARTS is thus straightforward and
can be performed in any lab with basic molecular biol-
ogy or biochemistry setup. It is also quick to carry out
and can be performed with any small molecule and
protein samples from any organism. Future improve-
ments in DARTS methodology are expected to increase
its sensitivity and decrease the number of proteolysis
conditions that must be tested for each small molecule.
The use of more sensitive proteomics techniques with
DARTS should greatly enhance its capability to identify
lower abundance targets, although which exact meth-
ods will prove most useful is to be determined. Further-
more, a nonproteomics approach using cDNA libraries
provides an alternative means to perform DARTS against
the proteins encoded by any genome of interest (62).
Last but not least, DARTS may also be used as a
means of target validation. It provides a simple and
fast method for verifying direct binding of small mol-
eculestopresumedtargetproteinsthatwereidentiﬁed
by alternative approaches. This may be particularly
useful when a list of potential target proteins is sus-
pected by phenotypic analysis or obtained through
omic screens or computational prediction (which may
implicate proteins of a particular complex or pathway
in the compound’s mechanism of action but are un-
able to show which protein if any is directly bound by
the drug (94)). DARTS can also be used to identify the
binding domain within the target protein because with
42 VOL.6 NO.1 • 34–46 • 2011 www.acschemicalbiology.org LOMENICK ET AL.more extensive protease treatment often the full-
length polypeptide of the target will not survive but a
smaller fragment corresponding to the binding domain
will retain protease resistance. For both target valida-
tion and target domain mapping, the robustness of
DARTS with proteins generated from DNA constructs
(e.g., expressed in cell lysates or by in vitro
transcription-translation) becomes extremely handy
(62, 94). With such versatility, DARTS is likely to
contribute considerably to the identiﬁcation and analy-
sis of drug–protein interactions for a long time to
come.
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